Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs from Ebola Virus Disease

Journal of Infectious Diseases

Volumn 217, Issue 3, 2018, Pages 451-455

  Meyer, Michelle ^a   Huang, Eric ^d   Yuzhakov, Olga ^c   Ramanathan, Palaniappan ^a   Ciaramella, Giuseppe ^c   Bukreyev, Alexander ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c Valera LLC   (United States)

^d MODERNA THERAPEUTICS   (United States)

Author keywords

antibody response; Ebola virus; immunization; RNA; vaccine

Indexed keywords

EBOLA VACCINE; IMMUNOGLOBULIN G ANTIBODY; MESSENGER RNA; NANOPARTICLE; NEUTRALIZING ANTIBODY; RNA VACCINE; SIGNAL PEPTIDE; VIRUS GLYCOPROTEIN; DRUG CARRIER; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; LIPOSOME; VIRUS ANTIBODY; VIRUS RNA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; FEMALE; GUINEA PIG; NONHUMAN; PRIORITY JOURNAL; VIREMIA; ANIMAL; BLOOD; DISEASE MODEL; IMMUNOLOGY; SURVIVAL ANALYSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; DRUG CARRIERS; EBOLA VACCINES; FEMALE; GUINEA PIGS; HEMORRHAGIC FEVER, EBOLA; IMMUNOGLOBULIN G; LIPOSOMES; RNA, MESSENGER; RNA, VIRAL; SURVIVAL ANALYSIS;

EID: 85041227397     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix592     Document Type: Article

References (15)

1. Kennedy SB, Bolay F, Kieh M, et al.; PREVAIL I Study Group. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in liberia. N Engl J Med 2017; 377:1438-47.
2. Huttner A, Dayer JA, Yerly S, et al.; VSV-Ebola Consortium. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: A randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 2015; 15:1156-66.
3. Chahal JS, Khan OF, Cooper CL, et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, Toxoplasma gondii challenges with a single dose. Proc Natl Acad Sci USA 2016; 113:E4133-42.
4. Sarwar UN, Costner P, Enama ME, et al.; VRC 206 Study Team. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis 2015; 211:549-57.
5. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465-8.
6. Richner JM, Himansu S, Dowd KA, et al. Modified mRNA vaccines protect against Zika virus infection. Cell 2017; 168:1114-25.e10.
7. Pardi N, Hogan MJ, Pelc RS, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 2017; 543:248-51.
8. Sahin U, Kariko K, Tureci O. mRNA-based therapeutics-developing a new class of drugs. Nat Rev Drug Discov 2014; 13:759-80.
9. Meyer M, Garron T, Lubaki NM, et al. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. J Clin Invest 2015; 125:3241-55.
10. Wong G, Richardson JS, Pillet S, et al. Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med 2012; 4:158ra46.
11. Petsch B, Schnee M, Vogel AB, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 2012; 30:1210-6.
12. Schnee M, Vogel AB, Voss D, et al. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl Trop Dis 2016; 10:e0004746.
13. Pardi N, Secreto AJ, Shan X, et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun 2017; 8:14630.
14. Bahl K, Senn JJ, Yuzhakov O, et al. Preclinical and clinical demonstration of immunogenicity by mRNA Vaccines against H10N8 and H7N9 influenza viruses. Mol Ther 2017; 25:1316-27.
15. Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013; 369:819-29.